Eloxx Pharmaceuticals Inc

Eloxx Pharmaceuticals, Inc. engages in the development of novel ribonucleic acid-modulating drug candidates. The firm focuses on the the formulation of medicines to treat rare and ultra-rare premature stop codon diseases. Its lead product candidate is ELX-02, a small molecule drug designed to restore production of full-length functional proteins. It operates through the United States and Israel geographical segments. The company was founded by Silvia Noiman on December 19, 2017 and is headquartered in Watertown, MA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WATERTOWN, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), today announced that the company has entered into a debt facility of up to $30.0 million with Hercules Capital, Inc. (NYSE: HTGC), a specialty financing lender for life science and technology companies. Eloxx has drawn the initial tranche of $12.5 million and used the proceeds to repay in full amounts outstanding under the Company's existing debt facility. The remaining funds under the new facility will be available in additional tranches upon the achievement of specific clinical milestones or other terms and conditions. For additional information please see our Current Report on Form 8-K filed with the SEC today.

Eloxx Pharmaceuticals Secures Debt Facility of Up to $30 Million from Hercules Capital

The stock price of Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) significantly increased today. This is why it happened.

ELOX Stock: Why It Increased Today

The FDA has granted Fast Track designation Eloxx Pharmaceuticals Inc's (NASDAQ: ELOX) ELX-02, a drug candidate intended to treat cystic fibrosis patients with nonsense mutations. ELX-02 is currently in Phase 2 clinical trials.

Eloxx Stock Moves Higher On Fast Track Tag For Cystic Fibrosis Candidate

Added Additional Treatment Arm and Provided Enrollment Update for Ongoing ELX-02 Phase 2 Clinical Trials for Cystic Fibrosis (CF)

Eloxx Pharmaceuticals Reports Second Quarter 2021 Financial and Operating Results and Provides Business Update

Dr Alan E. Walts joins Hemogenyx Pharmaceuticals team; renowned business leader brings industry experience in corporate and private venture capital, business development, R&D and general management. LONDON, UK / ACCESSWIRE / July 26, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces the appointment of Dr Alan E.

Hemogenyx Pharmaceuticals PLC Announces Appointment of Business Advisor & Board Observer

Data Readout for First Four Treatment Arms Expected in the Fourth Quarter of 2021 Data Readout for First Four Treatment Arms Expected in the Fourth Quarter of 2021

Eloxx Pharmaceuticals Provides Enrollment Update for Ongoing Phase 2 Clinical Studies for Cystic Fibrosis

Crescent Point Energy

Globus Maritime

Remark Hlds

Rave Restaurant Group

With July 4th on the way, which penny stocks are you watching right now? The post 7 Reddit Penny Stocks to Watch For the Long Weekend appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

7 Reddit Penny Stocks to Watch For the Long Weekend

The stock price of Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) increased by over 7% pre-market. This is why it happened.

ELOX Stock Price Increases Over 7% Pre-Market: Why It Happened

Investors need to pay close attention to Eloxx Pharmaceuticals (ELOX) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Eloxx Pharmaceuticals (ELOX) Stock?

Investors need to pay close attention to Eloxx (ELOX) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Eloxx (ELOX) Stock?

WALTHAM, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the closing of an underwritten public offering of 38,333,334 shares of common stock at a public offering price of $1.35 per share. The closing included the full exercise of the underwriters' option to purchase an additional 5,000,000 shares of common stock at the public offering price, less underwriting discounts and commissions. Aggregate gross proceeds from the offering were approximately $51.75 million, before deducting underwriting discounts and commissions and offering expenses.

Eloxx Pharmaceuticals, Inc. Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares

The stock price of Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) decreased by over 20% during intraday trading. This is why it happened.

Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) Stock: Over 20% Decrease Explanation

Bionano Genomics

CorMedix

Bionano Genomics, Inc. (NASDAQ: BNGO), CorMedix Inc. (NASDAQ: CRMD) and Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) are among the health care movers Friday. Bionano Moves On Q1 Results: Bionano reported first-quarter revenues of $3.2 million, up 179% year-over-year.

Why Bionano Genomics, CorMedix and Eloxx Are Moving Friday

WALTHAM, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the pricing of an underwritten public offering of 33,333,334 shares of common stock at a public offering price of $1.35 per share. In addition, the Company expects to grant the underwriters a 30-day option to purchase an additional 5,000,000 shares of common stock at the public offering price, less underwriting discounts and commissions.

Eloxx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock

Acquisition of Zikani Therapeutics, Ribosomal Modulation Company; Combined Company Advancing Ribosomal RNA-Targeted Genetic Therapies

Eloxx Pharmaceuticals Reports First Quarter 2021 Financial and Operating Results and Provides Business Update

Fifth Treatment Arm to Evaluate Safety of ELX-02 in Combination with Kalydeco (ivacaftor)

Eloxx Pharmaceuticals Adds Additional Treatment Arm to Ongoing Phase 2 Clinical Studies for Cystic Fibrosis

Eloxx Pharmaceuticals (ELOX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Eloxx Pharmaceuticals (ELOX) Is in Oversold Territory: What's Next?

Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) has acquired Zikani Therapeutics Inc in an all-stock transaction. The new entity will focus on ribosomal RNA-targeted therapies for the treatment of rare diseases and oncology.

Eloxx Stock is Trading Higher After Zikani Therapeutics Acquisition

The stock price of Eloxx Pharmaceuticals (NASDAQ: ELOX) increased by over 15% pre-market. This is why it happened.

Eloxx Pharmaceuticals Stock Price Increased Over 15% Pre-Market: Why It Happened

Combined Company to be Leader in Ribosomal RNA-Targeted Genetic Therapy Bringing Together Complementary Platforms

Eloxx Pharmaceuticals Acquires Zikani Therapeutics

Eloxx Pharmaceuticals, Inc. (ELOX) CEO Greg Williams on Q4 2020 Results - Earnings Call Transcript

We expect to report top line data from our Phase 2 cystic fibrosis clinical trials in the first half of this year

Eloxx Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operating Results and Provides Business Update

Company management to host a webcast and conference call to provide a business update and review financial results at 4:30 p.m. ET Company management to host a webcast and conference call to provide a business update and review financial results at 4:30 p.m. ET

Eloxx Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Business Update on March 11, 2021

Publication titled: “ A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of ELX-02 in Healthy Subjects”

Eloxx Announces Publication of Scientific Manuscript on ELX-02 in the Journal of Clinical Pharmacology in Drug Development

Publication titled: “Phase 1 Renal Impairment Trial Results Enable Targeted Individualized Dosing of ELX-02 in Nephropathic Cystinosis Patients” Publication titled: “Phase 1 Renal Impairment Trial Results Enable Targeted Individualized Dosing of ELX-02 in Nephropathic Cystinosis Patients”

News for Eloxx Pharmaceuticals Inc Stock (ELOX)